Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia Transcript

Core Points - The call discusses the FDA approval of Revuforj for its second indication in treating Relapsed/Refractory NPM1 Mutated AML [1][2] - Key executives from Syndax Pharmaceuticals are present on the call, including the CEO, Head of R&D, Chief Medical Officer, Chief Commercial Officer, and Chief Financial Officer [2] Company Overview - Syndax Pharmaceuticals is actively engaging with investors regarding the recent FDA approval, indicating a focus on communication and transparency [2][3] - The company has provided a slide deck on its Investor page, suggesting a structured approach to presenting information to stakeholders [3]